title: [Pleuropulmonary staphylococcal infection in infants, in a hospital environment in Ouagadougou (Burkina Faso)].
abstract: We observed 36 cases of pleuropulmonary staphylococcal infection (PPS) in infants aged 0 to 30 months, during a prospective study carried out between April 1st 1995 and March 31 1996 at the Pediatrics Department of Ouagadougou University Hospital. PPS accounted for 0.5% of all hospital admissions and 11.6% of all acute basal respiratory infections in children aged less than 30 months. Slightly more boys than girls were affected, with a sex ratio of 1.2. We identified the classic triad of symptoms: cough-fever-polypnea, associated with abdominal ballooning and a change in general condition. On X rays, the typical images showing parenchymatous bubbles were the second most frequent observation (27.8%) after parenchymatous opacities (69.5%). The most frequently used antibiotics were oxacillin (Bristopen), gentamycin (Gentallin) and cefuroxime-axetil (Zinnat). The prognosis of PPS is poor, with a high mortality rate (27.8%) and a risk of pleural recurrence. Being very young, late hospitalization, malnutrition and leukopenia were identified as factors indicating a poor prognosis. Recygling of health care personnel for the management of acute respiratory infections, a decrease in malnutrition and an improvement in vaccination cover are essential if the mortality and morbidity of acute respiratory infections, and PPS in particular, are to be reduced.
authors.affiliation: Service de pédiatrie, CHU de Ouagadougou, 03 BP 7022, Ouagadougou 03, Burkina Faso.
authors.forename: A
authors.initials: A
authors.lastname: Sawadogo
authors.forename: F
authors.initials: F
authors.lastname: Koueta
authors.forename: I
authors.initials: I
authors.lastname: Sanou
authors.forename: K L
authors.initials: KL
authors.lastname: Kam
authors.forename: L
authors.initials: L
authors.lastname: Dao
authors.forename: M
authors.initials: M
authors.lastname: Reinhardt
authors.forename: J
authors.initials: J
authors.lastname: Queloz
mesh_terms: D000367:Age Factors; D002050:Burkina Faso / Q000453:epidemiology; D002444:Cefuroxime / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D010068:Oxacillin / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D010995:Pleural Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D011023:Pneumonia, Staphylococcal / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D011446:Prospective Studies; D012307:Risk Factors; D012737:Sex Factors; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D002511:Cephalosporins; D005839:Gentamicins; D010406:Penicillins; D002444:Cefuroxime; D010068:Oxacillin